Clinical Trial: Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia Longitudinal Assessment Study

U.S., June 13 -- ClinicalTrials.gov registry received information related to the study (NCT07018401) titled 'Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia Longitudinal Assessment Study' on May 28.

Brief Summary: This is a multicenter U.S. longitudinal study evaluating patients with hereditary hemorrhagic telangiectasia who participated in the PATH-HHT clinical trial of pomalidomide for the treatment of HHT. This study is a longitudinal assessment of safety and effectiveness of pomalidomide in HHT in clinical trial participants following completion of the double-blind, placebo-controlled study.

Study Start Date: May 01, 2024

Study Type: OBSERVATIONAL

Condition: Hereditary Hemorrhagic Telangiectasia ...